Participated · Seed · Jul 2026

Respiro Diagnostics is developing a non-invasive liquid biopsy platform that captures DNA, RNA and proteins from exhaled breath using a proprietary breath collection device combined with laboratory analysis. The company positions its technology as an alternative to invasive tissue biopsies and blood-based liquid biopsies, aiming to support earlier diagnosis and provide molecular profiling to guide treatment decisions. Respiro has completed initial proof-of-concept testing in mesothelioma patients and plans to start its first lung cancer clinical study at Aalborg University Hospital in September 2026. The startup is also evaluating applications of its platform for other respiratory conditions such as pulmonary hypertension and asthma. Respiro is UK-based and was founded by Alison Quinn and Dr Theo Issitt. The company recently raised £1 million in a pre-seed round to fund clinical research and further development of its device and laboratory platform.

Participated · Seed · May 2026

NEX Health Intelligence builds predictive analytics intended to identify where drug‑resistant infections are likely to spread inside hospitals. The company’s technology is described as forecasting in-hospital transmission of antimicrobial‑resistant infections. TFN reported that NEX Health Intelligence raised €1M in new funding. The article does not provide revenue, user, or other operating metrics. No information on valuation, investor identities, or prior funding rounds was disclosed in the report.

Participated · Seed · Apr 2026

QMatter develops a quantum compression technology that reduces the size of complex quantum problems to their essential core so they can be computed on existing quantum and classical systems. The approach aims to extend capabilities of current and next-generation hardware by improving performance of classical algorithms and broadening the set of tractable problems. QMatter is initially focused on life sciences, working with pharmaceutical and biotechnology companies to improve simulations and accelerate R&D. The company is also building physics-informed data libraries intended to support training of advanced machine-learning models. Financially, QMatter has just completed a $1.2 million pre-seed round led by 55 North with participation from XTX Ventures, Bellstate Oy, and the Conception X Angel Syndicate. With the new funding, it plans to expand its platform and scale its simulation capabilities for scientific and industrial applications.

Participated · Seed · Dec 2025

Mater-AI has built a physics-informed, AI-powered platform that can design, generate and evaluate 100 new thermoelectric material structures every hour, reportedly speeding discovery up to 438× versus traditional R&D. The technology targets the 70 % of global energy that is currently lost as waste heat, aiming to supply novel materials for thermoelectric generators and coolers across data centres, defence, automotive and industrial IoT markets. By initially focusing on applications such as silent power sources, extended EV battery life and self-powered industrial sensors, the company believes it can unlock £3.4–4.6 billion in new market value. Over the next 6–8 weeks Mater-AI will begin lab testing of its first AI-discovered compounds with the University of Cambridge, Imperial College London and the Henry Royce Institute, feeding those results back into its models for rapid iteration. Within 12–18 months it aims to deliver a commercially viable material that outperforms today’s 5–7 % efficient standard while also being less toxic and more scalable. Founded by Dr Nickel Blankevoort (CEO), Gatleen Bhambra (COO) and Chelsea Williams (CTO), the company originates from research done at the University of Warwick. Financially, Mater-AI has secured £1.6 million to date (£100k in an initial cheque and £1.5 million in its main pre-seed round) to fund continued platform development and material validation.